Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Interferon

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    739 result(s) found for: Interferon. Displaying page 33 of 37.
    «« First « Previous 29  30  31  32  33  34  35  36  37  Next»
    EudraCT Number: 2012-002326-75 Sponsor Protocol Number: 8-55-58102-004 Start Date*: 2012-09-27
    Sponsor Name:Ipsen Pharma
    Full Title: A multicentre, open label, early stopping design, proof of concept study with tasquinimod in treating patients with advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas.
    Medical condition: advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas in patients who have progressed after standard therapies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003811-23 Sponsor Protocol Number: IMG-7289-CTP-102 Start Date*: 2019-12-11
    Sponsor Name:Imago BioSciences, Inc.
    Full Title: A Multi-Center, Open Label Study to Assess the Safety, Steady­ State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients with Myelofibrosis
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-003659-13 Sponsor Protocol Number: IMG-7289-CTP-201 Start Date*: 2020-06-21
    Sponsor Name:Imago BioSciences Inc.
    Full Title: A Phase 2 Multi-Center, Open Label Study to Assess the Safety,Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia
    Medical condition: Patients with essential thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015494 Essential thrombocythemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001044-54 Sponsor Protocol Number: Bosupeg Start Date*: 2018-10-04
    Sponsor Name:St Olavs Hospital -Trondheim University Hospital
    Full Title: A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS: A RANDOMIZED PROSPECTIVE TRIAL
    Medical condition: Chronic myeloid leukemia at diagnosis-chronich phase
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001550-29 Sponsor Protocol Number: AXI-IIG-02 Start Date*: 2011-08-11
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos
    Full Title: A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pa...
    Medical condition: Patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancreatic origin (carcinoids)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004537-20 Sponsor Protocol Number: 0761-016 Start Date*: 2021-07-22
    Sponsor Name:Kyowa Kirin Inc.
    Full Title: Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)
    Medical condition: Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) - Mycosis fungoides and Sezary syndrome
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10028510 Mycosis fungoides/Sezary syndrome recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001247-64 Sponsor Protocol Number: CRAD001C2239 Start Date*: 2006-06-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy
    Medical condition: Advanced pancreatic neuroendocrine tumors (NET).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001203-79 Sponsor Protocol Number: IM011021 Start Date*: 2017-12-04
    Sponsor Name:Bristol-Myers Squibb international Corporation
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017968 10042947 Systemic lupus erythematosus synd LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) DE (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-008258-21 Sponsor Protocol Number: NV20536 eu Start Date*: 2009-03-30
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegas...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003665-35 Sponsor Protocol Number: EIG-LMD-002 Start Date*: 2022-06-10
    Sponsor Name:Eiger BioPharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic He...
    Medical condition: Chronic Hepatitis Delta Virus (HDV) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10019762 Hepatitis D PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003836-38 Sponsor Protocol Number: MK-5172-077 Start Date*: 2015-02-16
    Sponsor Name:Merck Corporation, Inc.
    Full Title: A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) ES (Completed) NO (Completed) HU (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-000881-35 Sponsor Protocol Number: CLBH589B2202 Start Date*: 2007-01-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors
    Medical condition: Adult patients with chronic phase Ph+ CML whose disease is resistant following treatment with at least two BCR-ABL tyrosine kinase inhibitors (i.e. imitinib, nilotinib, or dasatinib).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009015 Chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) NL (Completed) FR (Completed) GB (Prematurely Ended) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004022-87 Sponsor Protocol Number: A6181111 Start Date*: 2007-04-05
    Sponsor Name:Pfizer Inc. [...]
    1. Pfizer Inc.
    2. Pfizer bv CR
    3. Pfizer bv RA
    Full Title: A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS
    Medical condition: Progressive, advanced/metastatic well-differentiated pancreatic islet cell tumours
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033632 Pancreatic neoplasms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) DK (Prematurely Ended) BE (Completed) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001778-17 Sponsor Protocol Number: 201190 Start Date*: 2016-03-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogeni...
    Medical condition: Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination).
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10019982 Herpes zoster NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002521-30 Sponsor Protocol Number: HBI-8000-303 Start Date*: 2022-03-07
    Sponsor Name:HUYABIO International, LLC
    Full Title: A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated w...
    Medical condition: Metastatic or unresectable melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004114-17 Sponsor Protocol Number: HPV-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Inovio Pharmaceuticals, Inc.
    Full Title: REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1...
    Medical condition: HPV-16 and/or HPV-18 related high grade squamous intraepithelial lesion (HSIL) of the cervix
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    20.0 100000004872 10066237 Cervical high grade squamous intraepithelial lesion LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) EE (Completed) ES (Restarted) PL (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003977-24 Sponsor Protocol Number: MK-3475-02B Start Date*: 2020-03-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Prematurely Ended) IT (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002125-11 Sponsor Protocol Number: CT-P13-3.5 Start Date*: 2016-08-23
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-000880-34 Sponsor Protocol Number: 207489 Start Date*: 2017-10-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine G...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000660-17 Sponsor Protocol Number: TPL108392 Start Date*: 2009-07-29
    Sponsor Name:GlaxoSmithKline
    Full Title: TPL108392: An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligibl...
    Medical condition: Thrombocytopenic subjects with hepatitis C viral infection (HCV)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) GR (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 29  30  31  32  33  34  35  36  37  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 21 07:47:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA